{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:08:46Z","timestamp":1792663726289,"version":"4.5.0"},"reference-count":106,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The traditional management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is difficult and often suboptimal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review improvements in the diagnosis and management of 21OHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Literature review, synthesis, and authors\u2019 experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>United States (2 centers).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 11-oxygenated androgens are abundant in 21OHD, and their measurement might improve diagnosis and medication titration. Several new treatments are under development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Circadian delivery of hydrocortisone improves disease management of 21OHD compared to conventional glucocorticoids. Glucocorticoid-sparing therapies such as crinecerfont and atumelnant offer the potential for a block-and-replace strategy, with physiologic replacement dosing of hydrocortisone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae759","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:26:16Z","timestamp":1729869976000},"page":"S74-S87","source":"Crossref","is-referenced-by-count":20,"title":["Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-3629","authenticated-orcid":false,"given":"Kyriakie","family":"Sarafoglou","sequence":"first","affiliation":[{"name":"Departments of Pediatrics, Divisions of Pediatric Endocrinology and Genetics & Metabolism, University of Minnesota Medical School , Minneapolis, MN 55454 ,","place":["USA"]},{"name":"Department of Experimental and Clinical Pharmacology, University of Minnesota School of Pharmacy , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-6181","authenticated-orcid":false,"given":"Richard J","family":"Auchus","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School , Ann Arbor, MI 48109 ,","place":["USA"]},{"name":"LTC Charles S. Kettles Veterans Affairs Medical Center , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"1","key":"2025012714362468200_dgae759-B1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"issue":"12","key":"2025012714362468200_dgae759-B2","first-page":"4589","article-title":"11-Ketotestosterone is the dominant circulating bioactive androgen during normal and premature adrenarche","volume":"103","author":"Rege","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1-2","key":"2025012714362468200_dgae759-B3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mce.2013.07.006","article-title":"11\u03b2-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?","volume":"377","author":"Storbeck","year":"2013","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"2025012714362468200_dgae759-B4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2025012714362468200_dgae759-B5","doi-asserted-by":"crossref","first-page":"bvaa192","DOI":"10.1210\/jendso\/bvaa192","article-title":"11-Oxygenated androgens useful in the setting of discrepant conventional biomarkers in 21-hydroxylase deficiency","volume":"5","author":"Jha","year":"2021","journal-title":"J Endocr Soc"},{"issue":"1","key":"2025012714362468200_dgae759-B6","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1210\/clinem\/dgab598","article-title":"Production of 11-oxygenated androgens by testicular adrenal rest tumors","volume":"107","author":"Schroder","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025012714362468200_dgae759-B7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-19-0905","article-title":"Abiraterone acetate treatment lowers 11-oxygenated androgens","volume":"182","author":"Wright","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025012714362468200_dgae759-B8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/JIM.0000000000000121","article-title":"Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia","volume":"63","author":"Sarafoglou","year":"2015","journal-title":"J Investig Med"},{"issue":"3","key":"2025012714362468200_dgae759-B9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/bcp.14470","article-title":"An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia","volume":"87","author":"Al-Kofahi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2025012714362468200_dgae759-B10","doi-asserted-by":"crossref","first-page":"e1729","DOI":"10.1210\/clinem\/dgaa071","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia","volume":"105","author":"Melin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025012714362468200_dgae759-B11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/03091902.2013.773096","article-title":"Automated 24-hours sampling of subcutaneous tissue free cortisol in humans","volume":"37","author":"Bhake","year":"2013","journal-title":"J Med Eng Technol"},{"issue":"4","key":"2025012714362468200_dgae759-B12","doi-asserted-by":"crossref","first-page":"e1749","DOI":"10.1210\/clinem\/dgz002","article-title":"Continuous free cortisol profiles in healthy men","volume":"105","author":"Bhake","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"701","key":"2025012714362468200_dgae759-B13","doi-asserted-by":"crossref","first-page":"eadg8464","DOI":"10.1126\/scitranslmed.adg8464","article-title":"High-resolution daily profiles of tissue adrenal steroids by portable automated collection","volume":"15","author":"Upton","year":"2023","journal-title":"Sci Transl Med"},{"issue":"2","key":"2025012714362468200_dgae759-B14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/joim.13795","article-title":"Circadian and ultradian rhythms: clinical implications","volume":"296","author":"Lightman","year":"2024","journal-title":"J Intern Med"},{"issue":"12","key":"2025012714362468200_dgae759-B15","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1210\/jc.2019-00031","article-title":"Measurement of salivary adrenal-specific androgens as biomarkers of therapy control in 21-hydroxylase deficiency","volume":"104","author":"Bacila","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025012714362468200_dgae759-B16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/archdischild-2017-313873","article-title":"Update on adrenal steroid hormone biosynthesis and clinical implications","volume":"104","author":"Bacila","year":"2019","journal-title":"Arch Dis Child"},{"key":"2025012714362468200_dgae759-B17","doi-asserted-by":"crossref","first-page":"751191","DOI":"10.3389\/fendo.2021.751191","article-title":"24-Hour profiles of 11-oxygenated C19 steroids and \u03945-steroid sulfates during oral and continuous subcutaneous glucocorticoids in 21-hydroxylase deficiency","volume":"12","author":"Turcu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2025012714362468200_dgae759-B18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000526485","article-title":"Salivary 17-hydroxyprogesterone levels in children with congenital adrenal hyperplasia: a retrospective longitudinal study considering auxological parameters","volume":"96","author":"Dubinski","year":"2023","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"2025012714362468200_dgae759-B19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1515\/jpem-2024-0027","article-title":"Diurnal 11-ketotestosterone and 17-hydroxyprogesterone saliva profiles in paediatric classical congenital adrenal hyperplasia","volume":"37","author":"Dubinski","year":"2024","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"11","key":"2025012714362468200_dgae759-B20","doi-asserted-by":"crossref","first-page":"e4509","DOI":"10.1210\/clinem\/dgab446","article-title":"Salivary profiles of 11-oxygenated androgens follow a diurnal rhythm in patients with congenital adrenal hyperplasia","volume":"106","author":"Nowotny","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025012714362468200_dgae759-B21","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1210\/clinem\/dgab826","article-title":"Optimizing the timing of highest hydrocortisone dose in children and adolescents with 21-hydroxylase deficiency","volume":"107","author":"Schroder","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025012714362468200_dgae759-B22","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/cen.12551","article-title":"Elevated hair cortisol concentrations in children with adrenal insufficiency on hydrocortisone replacement therapy","volume":"81","author":"Noppe","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025012714362468200_dgae759-B23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/cen.13078","article-title":"Scalp hair 17-hydroxyprogesterone and androstenedione as a long-term therapy monitoring tool in congenital adrenal hyperplasia","volume":"85","author":"Noppe","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11-12","key":"2025012714362468200_dgae759-B24","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1159\/000504672","article-title":"Steroid 17-hydroxyprogesterone in hair is a potential long-term biomarker of androgen control in congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Auer","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2025012714362468200_dgae759-B25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jcem-33-1-14","article-title":"Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects","volume":"33","author":"Weitzman","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025012714362468200_dgae759-B26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/2042018810380214","article-title":"Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy","volume":"1","author":"Chan","year":"2010","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"2025012714362468200_dgae759-B27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/EJE-07-0052","article-title":"Continuous subcutaneous hydrocortisone infusion in Addison's disease","volume":"157","author":"Lovas","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025012714362468200_dgae759-B28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.2006.02544.x","article-title":"Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia","volume":"65","author":"Merza","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2025012714362468200_dgae759-B29","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1210\/jc.2013-4253","article-title":"Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial","volume":"99","author":"Oksnes","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025012714362468200_dgae759-B30","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1210\/jc.2016-1916","article-title":"A phase 2 study of continuous subcutaneous hydrocortisone infusino in adults with congenital adrenal hyperplasia","volume":"101","author":"Nella","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025012714362468200_dgae759-B31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cen.13813","article-title":"Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia","volume":"89","author":"Mallappa","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025012714362468200_dgae759-B32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/EJE-20-0787","article-title":"Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective series of five patients","volume":"184","author":"Bachelot","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2025012714362468200_dgae759-B33","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1210\/clinem\/dgaa381","article-title":"A phase 2, multicenter study of nevanimibe for the treatment of congenital adrenal hyperplasia","volume":"105","author":"El-Maouche","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025012714362468200_dgae759-B34","first-page":"3535","article-title":"A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia","volume":"81","author":"Laue","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025012714362468200_dgae759-B35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1210\/jcem.85.3.6462","article-title":"Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia","volume":"85","author":"Merke","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025012714362468200_dgae759-B36","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1210\/jc.2014-1258","article-title":"Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency","volume":"99","author":"Auchus","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025012714362468200_dgae759-B37","author":"Adrenas Therapeutics"},{"issue":"5","key":"2025012714362468200_dgae759-B38","doi-asserted-by":"crossref","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","article-title":"Modified-release hydrocortisone in congenital adrenal hyperplasia","volume":"106","author":"Merke","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025012714362468200_dgae759-B39","doi-asserted-by":"crossref","first-page":"e1433","DOI":"10.1210\/clinem\/dgaa626","article-title":"A prospective study of children aged 0-8 years with CAH and adrenal insufficiency treated with hydrocortisone granules","volume":"106","author":"Neumann","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025012714362468200_dgae759-B40","doi-asserted-by":"crossref","first-page":"e4666","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2025012714362468200_dgae759-B41","author":"Spruce Biosciences"},{"issue":"3","key":"2025012714362468200_dgae759-B42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/clinem\/dgab749","article-title":"Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"107","author":"Auchus","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025012714362468200_dgae759-B43","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1210\/clinem\/dgad270","article-title":"Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia","volume":"108","author":"Newfield","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025012714362468200_dgae759-B44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2404655","article-title":"Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia","volume":"391","author":"Sarafoglou","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2025012714362468200_dgae759-B45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2404656","article-title":"Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Auchus","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2025012714362468200_dgae759-B46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/cen.14009","article-title":"Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: impact of anastrozole on bone mineral density and visceral adipose tissue","volume":"91","author":"Halper","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025012714362468200_dgae759-B47","first-page":"A83","article-title":"Inhibition of basal and ACTH-stimulated cortisol secretion in humans using an oral nonpeptide ACTH antagonist (CRN04894)","volume":"6(Suppl 1)","author":"Krasner","year":"2022","journal-title":"J Endocr Soc"},{"key":"2025012714362468200_dgae759-B48","first-page":"A133","article-title":"Once daily oral atumelnant (CRN04894) induces rapid and profound reductions of androstenedione and 17-hydroxyprogesterone in participants with classical congenital adrenal hyperplasia: initial results from a 12-week, phase 2, open-label study","volume":"8(Suppl 1)","author":"Auchus","year":"2024","journal-title":"J Endocr Soc"},{"key":"2025012714362468200_dgae759-B49","first-page":"A152","article-title":"Safety and pharmacokinetics of anti-ACTH antibody Lu AG13909 in patients with classic congenital adrenal hyperplasia: phase 1 open-label, multiple-ascending-dose trial protocol","volume":"8(Suppl 1)","author":"Srirangalingam","year":"2024","journal-title":"J Endocr Soc"},{"issue":"9","key":"2025012714362468200_dgae759-B50","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1210\/clinem\/dgad134","article-title":"Interpretation of steroid biomarkers in 21-jydroxylase deficiency and their use in disease management","volume":"108","author":"Sarafoglou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025012714362468200_dgae759-B51","doi-asserted-by":"crossref","first-page":"bvaa091","DOI":"10.1210\/jendso\/bvaa091","article-title":"Manipulation of hydrocortisone tablets leads to iatrogenic cushing syndrome in a 6-year-old girl with CAH","volume":"4","author":"Al-Rayess","year":"2020","journal-title":"J Endocr Soc"},{"issue":"1","key":"2025012714362468200_dgae759-B52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1210\/jc.2017-01595","article-title":"Iatrogenic cushing syndrome in a child with congenital adrenal hyperplasia: erroneous compounding of hydrocortisone","volume":"103","author":"Barillas","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025012714362468200_dgae759-B53","doi-asserted-by":"crossref","first-page":"e000198","DOI":"10.1136\/bmjpo-2017-000198","article-title":"Content uniformity of quartered hydrocortisone tablets in comparison with mini-tablets for paediatric dosing","volume":"2","author":"Madathilethu","year":"2018","journal-title":"BMJ Paediatr Open"},{"issue":"12","key":"2025012714362468200_dgae759-B54","first-page":"1871","article-title":"Practice variation among pediatric endocrinologists in the dosing of glucocorticoids in young children with congenital adrenal hyperplasia","volume":"10","author":"Al-Rayess","year":"2023","journal-title":"Children (Basel)"},{"issue":"1-2","key":"2025012714362468200_dgae759-B55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2018.04.054","article-title":"How close is the dose? Manipulation of 10\u202fmg hydrocortisone tablets to provide appropriate doses to children","volume":"545","author":"Watson","year":"2018","journal-title":"Int J Pharm"},{"issue":"1","key":"2025012714362468200_dgae759-B56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1210\/jcem.86.1.7275","article-title":"Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia","volume":"86","author":"Merke","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025012714362468200_dgae759-B57","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1210\/jc.2014-4060","article-title":"Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency","volume":"100","author":"Whitaker","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025012714362468200_dgae759-B58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen.13447","article-title":"Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency","volume":"88","author":"Neumann","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2025012714362468200_dgae759-B59","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1210\/js.2018-00380","article-title":"Hydrocortisone granules are bioequivalent when sprinkled onto food or given directly on the tongue","volume":"3","author":"Daniel","year":"2019","journal-title":"J Endocr Soc"},{"issue":"11","key":"2025012714362468200_dgae759-B60","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025012714362468200_dgae759-B61","first-page":"66","article-title":"Stability of an alcohol-free, dye-free hydrocortisone (2\u2005mg\/mL) compounded oral suspension","volume":"22","author":"Manchanda","year":"2018","journal-title":"Int J Pharm Compd"},{"key":"2025012714362468200_dgae759-B62","first-page":"100","article-title":"Stability of hydrocortisone in extemporaneously compounded suspension","volume":"13","author":"Chong","year":"2003","journal-title":"J Inform Pharmacother"},{"issue":"4","key":"2025012714362468200_dgae759-B63","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/jcph.424","article-title":"Comparison of cortisol exposures and pharmacodynamic adrenal steroid responses to hydrocortisone suspension vs. commercial tablets","volume":"55","author":"Sarafoglou","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2025012714362468200_dgae759-B64","doi-asserted-by":"crossref","first-page":"bvab193","DOI":"10.1210\/jendso\/bvab193","article-title":"Bone age maturation and growth outcomes in young children with CAH treated with hydrocortisone suspension","volume":"6","author":"Al-Rayess","year":"2022","journal-title":"J Endocr Soc"},{"issue":"1","key":"2025012714362468200_dgae759-B65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-013-0005-9","article-title":"Potential risks of pharmacy compounding","volume":"13","author":"Gudeman","year":"2013","journal-title":"Drugs R D"},{"issue":"11","key":"2025012714362468200_dgae759-B66","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1210\/en.2015-1367","article-title":"Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells","volume":"156","author":"Sbiera","year":"2015","journal-title":"Endocrinology"},{"issue":"7808","key":"2025012714362468200_dgae759-B67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41586-020-2295-8","article-title":"Structure of nevanimibe-bound tetrameric human ACAT1","volume":"581","author":"Long","year":"2020","journal-title":"Nature"},{"issue":"28","key":"2025012714362468200_dgae759-B68","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025012714362468200_dgae759-B69","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1073\/pnas.92.7.2969","article-title":"Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart","volume":"92","author":"Perrin","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2025012714362468200_dgae759-B70","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1073\/pnas.90.19.8967","article-title":"Expression cloning of a human corticotropin-releasing-factor receptor","volume":"90","author":"Chen","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9-10","key":"2025012714362468200_dgae759-B71","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00213-017-4556-2","article-title":"Don't stress about CRF: assessing the translational failures of CRF1antagonists","volume":"234","author":"Spierling","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"2025012714362468200_dgae759-B72","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2015-3574","article-title":"Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency","volume":"101","author":"Turcu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025012714362468200_dgae759-B73","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-3476(05)80128-3","article-title":"Cortisol production rate in childhood and adolescence","volume":"117","author":"Linder","year":"1990","journal-title":"J Pediatr"},{"issue":"1","key":"2025012714362468200_dgae759-B74","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/jc.2003-030440","article-title":"Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women","volume":"89","author":"Purnell","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025012714362468200_dgae759-B75","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jpeds.2014.01.011","article-title":"Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort","volume":"164","author":"Sarafoglou","year":"2014","journal-title":"J Pediatr"},{"issue":"9","key":"2025012714362468200_dgae759-B76","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1210\/jc.2009-2616","article-title":"Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis","volume":"95","author":"Muthusamy","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025012714362468200_dgae759-B77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1067\/mpd.2001.110527","article-title":"Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis","volume":"138","author":"Eugster","year":"2001","journal-title":"J Pediatr"},{"issue":"1-2","key":"2025012714362468200_dgae759-B78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"12","key":"2025012714362468200_dgae759-B79","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1210\/jc.2005-1392","article-title":"Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial","volume":"90","author":"Hero","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"9270","key":"2025012714362468200_dgae759-B80","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0140-6736(00)04895-9","article-title":"A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial","volume":"357","author":"Wickman","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"2025012714362468200_dgae759-B81","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2265.2006.02499.x","article-title":"Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty","volume":"64","author":"Hero","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025012714362468200_dgae759-B82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1297\/cpe.23.53","article-title":"Third-generation aromatase inhibitor improved adult height in a Japanese boy with testotoxicosis","volume":"23","author":"Yoshizawa-Ogasawara","year":"2014","journal-title":"Clin Pediatr Endocrinol"},{"issue":"4","key":"2025012714362468200_dgae759-B83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40618-015-0399-z","article-title":"Anastrozole plus leuprorelin in early maturing girls with compromised growth: the \u201cGAIL\u201d study","volume":"39","author":"Papadimitriou","year":"2016","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2025012714362468200_dgae759-B84","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/jc.2007-1559","article-title":"Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years","volume":"93","author":"Mauras","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025012714362468200_dgae759-B85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endrev\/bnac014","article-title":"Management of growth disorders in puberty: GH, GnRHa, and aromatase inhibitors: a clinical review","volume":"44","author":"Mauras","year":"2023","journal-title":"Endocr Rev"},{"issue":"2","key":"2025012714362468200_dgae759-B86","doi-asserted-by":"crossref","first-page":"e20160730","DOI":"10.1542\/peds.2016-0730","article-title":"Growth hormone with aromatase inhibitor may improve height in CYP11B1 congenital adrenal hyperplasia","volume":"139","author":"Hawton","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"2025012714362468200_dgae759-B87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000501746","article-title":"Aromatase inhibitor as treatment for severely advanced bone age in congenital adrenal hyperplasia: a case report","volume":"92","author":"Goedegebuure","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2025012714362468200_dgae759-B88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13633-015-0008-0","article-title":"Height augmentation in 11\u03b2-hydroxylase deficiency congenital adrenal hyperplasia","volume":"2015","author":"Nour","year":"2015","journal-title":"Int J Pediatr Endocrinol"},{"issue":"3","key":"2025012714362468200_dgae759-B89","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000501456","article-title":"Restoration of height after 11 years of letrozole treatment in 11\u03b2-hydroxylase deficiency","volume":"92","author":"Atay","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"2025012714362468200_dgae759-B90","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae771","article-title":"Anastrozole improves height outcomes in growing children with congenital adrenal hyperplasia due to 21-OHD","author":"Al-Rayess","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2025012714362468200_dgae759-B91","doi-asserted-by":"crossref","first-page":"1101843","DOI":"10.3389\/fendo.2023.1101843","article-title":"Case report: anastrozole as a monotherapy for pre-pubertal children with non-classic congenital adrenal hyperplasia","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2025012714362468200_dgae759-B92","first-page":"2370","article-title":"Estrogen suppression in males: metabolic effects","volume":"85","author":"Mauras","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025012714362468200_dgae759-B93","first-page":"1","article-title":"ALD1613, a novel long-acting monoclonal antibody to control ACTH-driven pharmacology","volume":"158","author":"Feldhaus","year":"2017","journal-title":"Endocrinology"},{"issue":"7","key":"2025012714362468200_dgae759-B94","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/en.2019-00117","article-title":"A long-acting neutralizing monoclonal ACTH antibody blocks corticosterone and adrenal gene responses in neonatal rats","volume":"160","author":"Gehrand","year":"2019","journal-title":"Endocrinology"},{"issue":"11","key":"2025012714362468200_dgae759-B95","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/sj.gt.3301018","article-title":"Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochrome P450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice","volume":"6","author":"Tajima","year":"1999","journal-title":"Gene Ther"},{"issue":"5","key":"2025012714362468200_dgae759-B96","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/gt.2017.10","article-title":"An AAVrh10-CAG-CYP21-HA vector allows persistent correction of 21-hydroxylase deficiency in a Cyp21(-\/-) mouse model","volume":"24","author":"Perdomini","year":"2017","journal-title":"Gene Ther"},{"issue":"10","key":"2025012714362468200_dgae759-B97","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1507\/endocrj.EJ16-0112","article-title":"Extra-adrenal induction of Cyp21a1 ameliorates systemic steroid metabolism in a mouse model of congenital adrenal hyperplasia","volume":"63","author":"Naiki","year":"2016","journal-title":"Endocr J"},{"issue":"4","key":"2025012714362468200_dgae759-B98","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/hum.2017.203","article-title":"Biology of the adrenal gland cortex obviates effective use of adeno-associated virus vectors to treat hereditary adrenal disorders","volume":"29","author":"Markmann","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"6","key":"2025012714362468200_dgae759-B99","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.devcel.2013.07.016","article-title":"Adrenocortical zonation results from lineage conversion of differentiated zona glomerulosa cells","volume":"26","author":"Freedman","year":"2013","journal-title":"Dev Cell"},{"issue":"2","key":"2025012714362468200_dgae759-B100","doi-asserted-by":"crossref","first-page":"101232","DOI":"10.1016\/j.omtm.2024.101232","article-title":"AAV-delivered hepato-adrenal cooperativity in steroidogenesis: implications for gene therapy for congenital adrenal hyperplasia","volume":"32","author":"Graves","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"Suppl 1","key":"2025012714362468200_dgae759-B101","doi-asserted-by":"crossref","first-page":"Abstract OR25-01","DOI":"10.1210\/jendso\/bvaa046.899","article-title":"Durable CYP21A2 gene therapy in non-human primates for treatment of congenital adrenal hyperplasia","volume":"4","author":"Eclov","year":"2020","journal-title":"J Endocr Soc"},{"issue":"9","key":"2025012714362468200_dgae759-B102","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/clinem\/dgaa438","article-title":"New horizons: novel adrenal regenerative therapies","volume":"105","author":"Bornstein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025012714362468200_dgae759-B103","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1073\/pnas.1500242112","article-title":"Transplantation of bovine adrenocortical cells encapsulated in alginate","volume":"112","author":"Balyura","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"2025012714362468200_dgae759-B104","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1016\/j.devcel.2022.10.010","article-title":"Reconstitution of human adrenocortical specification and steroidogenesis using induced pluripotent stem cells","volume":"57","author":"Sakata","year":"2022","journal-title":"Dev Cell"},{"issue":"5","key":"2025012714362468200_dgae759-B105","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.celrep.2018.01.003","article-title":"Modeling congenital adrenal hyperplasia and testing interventions for adrenal insufficiency using donor-specific reprogrammed cells","volume":"22","author":"Ruiz-Babot","year":"2018","journal-title":"Cell Rep"},{"issue":"11","key":"2025012714362468200_dgae759-B106","doi-asserted-by":"crossref","first-page":"100627","DOI":"10.1016\/j.crmeth.2023.100627","article-title":"Generation of glucocorticoid-producing cells derived from human pluripotent stem cells","volume":"3","author":"Ruiz-Babot","year":"2023","journal-title":"Cell Rep Methods"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/Supplement_1\/S74\/61529784\/dgae759.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/Supplement_1\/S74\/61529784\/dgae759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T09:37:01Z","timestamp":1737970621000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/Supplement_1\/S74\/7965805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":106,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,1,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae759","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,1,21]]}}}